Progress and Challenges in Measles and Rubella Elimination in the WHO European Region
Vaccines · 20.06.2024 · 12 (6) · 696
DOI: 10.3390/vaccines12060696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 20.06.2024. Verfasst von Mark Muscat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
The elimination of both measles and rubella remains a priority for all 53 Member States of the World Health Organization (WHO) European Region. To provide an update on the epidemiological status of measles and rubella in the Region, we reviewed surveillance data on both diseases for 2023 submitted monthly by national surveillance institutions. We analyzed the cases of measles and rubella for 2023 by age group, case classification, vaccination, hospitalization, and importation status and report on measles-related deaths. In 2023, 60,860 measles cases, including 13 fatal cases, were reported in 41 countries. Most cases (95%; n = 57,584) were reported by six countries: Azerbaijan, Kazakhstan, Kyrgyzstan, Romania, the Russian Federation, and Türkiye. Of the 60,848 cases with data on age, 19,137 (31%) were 1–4 years old and 12,838 (21%) were 5–9 years old. A total of 10,412 (17%) were 20 years and older. The genotypes identified in the Region were largely dominated by D8 variants (n = 1357) and the remainder were B3 variants (n = 221). In 2023, 345 rubella cases were reported by 17 countries, mostly from Poland, Kyrgyzstan, Tajikistan, Türkiye, and Ukraine. A total of 262 cases (76%) were classified as clinically compatible and 79 (23%) were laboratory-confirmed. To achieve the elimination of measles and rubella in the Region, political commitment needs to be revived to enable urgent efforts to increase vaccination coverage, improve surveillance and outbreak preparedness, and respond immediately to outbreaks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark.
ORCID-Profile: Mark Muscat, José Hagan
Förderung
- World Health Organization
Zitieren
APA
Muscat, M., Ben Mamou, M., Reynen-de Kat, C., Jankovic, D., Hagan, J., Singh, S., & Datta, S. S. (2024). Progress and Challenges in Measles and Rubella Elimination in the WHO European Region. Vaccines, 12(6), 696. https://doi.org/10.3390/vaccines12060696
Vancouver
Muscat M, Ben Mamou M, Reynen-de Kat C, Jankovic D, Hagan J, Singh S, et al. Progress and Challenges in Measles and Rubella Elimination in the WHO European Region. Vaccines. 2024;12(6):696. doi:10.3390/vaccines12060696
BibTeX
@article{Muscat2024,
author = {Muscat, Mark and Ben Mamou, Myriam and Reynen-de Kat, Catharina and Jankovic, Dragan and Hagan, José and Singh, Simarjit and Datta, Siddhartha Sankar},
title = {Progress and Challenges in Measles and Rubella Elimination in the WHO European Region},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {6},
pages = {696},
doi = {10.3390/vaccines12060696}
}
EUVIMED